Overview

Improving Pregnancy Outcomes With Progesterone

Status:
Completed
Trial end date:
2020-08-06
Target enrollment:
Participant gender:
Summary
This is a phase III, double-masked, placebo-controlled, randomized controlled trial taking place in Zambia.
Phase:
Phase 3
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborators:
AMAG Pharmaceuticals, Inc.
Bill and Melinda Gates Foundation
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Treatments:
11-hydroxyprogesterone
17 alpha-Hydroxyprogesterone Caproate
17-alpha-hydroxy-progesterone caproate
Progesterone